It was a banner week in the micro-cap space, assuming your definition of "banner" involves mass executive resignations, auditor musical chairs, and balance sheets so distressed they require medical attention. Capital is expensive, patience is thin, and the consequences of multi-year cash burns are finally arriving. Here is what happened in the basement of the public markets this week.
Trinseo PLC (TSEOF): The One-Cent Wipeout
If you owe $2 billion you cannot pay, you file for a prepackaged Chapter 11 bankruptcy. If you are an equity holder in a company that owes $2 billion it cannot pay, your stock is worth zero. Trinseo filed its voluntary petition on Tuesday to shed $140 million in annual interest expenses. The company called this a "proactive step" to strengthen its financial foundation, which is a polite way of saying existing lenders are taking the keys. Following its NYSE delisting in March, the stock is now trading OTC under TSEOF at exactly one cent per share, down roughly 94% from its previous close.
AIxCrypto Holdings (AIXC): Nepotism and Crypto Pivots
You might remember Qualigen Therapeutics as a clinical-stage biotech company. It is now AIxCrypto Holdings, a Nasdaq-listed "Embodied AI and RWA Tokenization" company, because sometimes you just have to lean into the buzzwords. This week, the company announced the immediate resignation of its Co-CEO, President, and CFO. In their place, the board appointed Jerry Wang, who conveniently happens to be the nephew of the CEO of the company's majority shareholder, Yueting Jia. The new leadership immediately voted to permanently discontinue the legacy biotech business. The company hasn't disclosed the financial impact of the wind-down yet, but when you replace your entire C-suite in an afternoon to pivot from biotech to crypto, the impairment charges usually follow.
Actinium Pharmaceuticals (ATNM): The PR Distraction Playbook
The NYSE American requires listed companies to maintain $4.0 million in stockholders' equity if they have chronic multi-year losses. Actinium has $2.3 million. On Wednesday, the exchange sent a deficiency notice giving the company until June 26 to submit a compliance plan, slapping a ".BC" (below compliance) indicator on the ticker. Actinium executed the classic micro-cap defense mechanism: immediately issue a press release about something else. Two days after the notice, they announced they would present new preclinical data for their radioconjugate program at the SNMMI 2026 conference. The distraction actually worked. Shares popped nearly 10% on the news, proving that retail investors will forgive a balance sheet crisis if you promise them decent lab results.
Century Casinos (CNTY): Fleeing the Scene
Changing your independent auditor is a routine administrative event. Changing your auditor right after disclosing material weaknesses in internal controls and restating your financials for 2024 and 2025 is the accounting equivalent of fleeing the scene of a crash. Century Casinos dismissed Grant Thornton on May 22 and handed the mess to Ernst & Young. The filings indicate there were no formal disagreements, which is standard boilerplate, but the timing speaks for itself. EY is stepping into an engagement where the internal controls over financial reporting have already been publicly admitted to be broken.
FingerMotion (FNGR): The $68k Public Company
FingerMotion is a Nasdaq-listed telecommunications and data analytics company that finished its fiscal year with exactly $68,596 in cash. Against that mid-five-figure bank balance, the company posted an annual net loss of $7.0 million. Core telecom revenue cratered 32%, and marketing spend was slashed by 70% just to keep the lights on. The earnings report did feature one bright spot: their "Data and Analytics" segment grew 148% year-over-year. It generated a grand total of $27,780. The company operates via a Variable Interest Entity (VIE) in China, meaning US investors own a contract, not the actual operating assets—an unappealing structure even when the company isn't facing an immediate liquidity crisis.
What to Watch Next
Keep an eye on Actinium's June 26th deadline; they either need to raise capital at highly dilutive prices or face delisting proceedings. Look for AIxCrypto's upcoming periodic report to quantify exactly how much cash their biotech wind-down will burn. As for FingerMotion, a company burning millions cannot survive on $68,000 for more than a few weeks. Expect an emergency, highly dilutive capital raise imminently, assuming they can find a buyer.